Dr. Lise Lund Kjems, Chief Medical Officer at Cyclo Therapeutics, talks about Cyclo’s investigational therapy for Niemann-Pick Disease Type C and gives insight into rare disease drug development, with an emphasis on ensuring trial design includes holistic and specific patient concerns.